biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > Prothena option

<< Previous

Bullboard Posts

Next >>

Comment by zwerp2000on Jan 31, 2021 12:04pm

172 Views

Post# 32431472

RE:Prothena option

I would've read too much into it. It could just be standard language where they don't want to give investors unjustified expectations. If prothena was not interested, why not just end the deal instead of extending it? I woujd venture to say perhaps Bioaf doesn't know what prothena is going to do after the 3 month extension. Hell, maybe prothena doesn't even know yet. Maybe our oracle, JD, could provide his thoughts. Unless we just have to wait for it to come out on his website. Btw, Where is his website? He talks about it a lot but I haven't seen it.

<< Previous

Bullboard Posts

Next >>

Sony’s Alpha 1 II: A new professional photography standard?